PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30322329-1	2019	Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy.	asct	199-203	programmed cell death 1	Homo sapiens	0-18
31953963-3	2020	We retrospectively reviewed 414 FL patients treated with ASCT between 2000 and 2014 in four hematology departments.	asct	57-61	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	32-34
31231123-0	2020	XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT.	asct	126-130	X-ray repair cross complementing 1	Homo sapiens	0-5
30322329-1	2019	Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy.	asct	199-203	programmed cell death 1	Homo sapiens	20-24
30700844-4	2019	CRH was better with ASCT (49.7%) than with MDex (37.7%, p = 0.001).	asct	20-24	corticotropin releasing hormone	Homo sapiens	0-3
29957865-15	2018	In younger patients with untreated MCL, R-High-CHOP/CHASER/LEED with ASCT showed high efficacy and acceptable toxicity, and it can now be considered a standard treatment option.	asct	69-73	DNA damage inducible transcript 3	Homo sapiens	47-51
21220034-11	2011	The gain of the IL-6R gene was frequent in myeloma, showing an association with adverse prognosis in myeloma patients treated with ASCT.	asct	131-135	interleukin 6 receptor	Homo sapiens	16-21
29348129-3	2018	All patients received TKI and aSCT in first complete remission (CR1).	asct	30-34	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	64-67
23765188-15	2013	CONCLUSION: Myeloablative RIT with 131I-rituximab followed by ASCT is feasible, well-tolerated and effective in high risk CD20+ NHL.	asct	62-66	keratin 20	Homo sapiens	122-126
22712536-2	2012	We carried out a single-arm study to assess the toxicity and efficacy of a short block of consolidation therapy with cyclophosphamide, low dose thalidomide and dexamethasone (CTD) in patients within 6 months following ASCT, as part of frontline therapy for symptomatic multiple myeloma.	asct	218-222	CTD	Homo sapiens	175-178
27072903-1	2016	Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes.	asct	227-231	prion like protein doppel	Homo sapiens	79-82
20367136-2	2010	Adding rituximab (R) to the initial therapy has improved outcomes; however, the benefit of ASCT for chemosensitive patients who fail R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, prednisone) is unclear.	asct	91-95	DNA damage inducible transcript 3	Homo sapiens	135-139
18096567-5	2008	Responding bcl-2+ patients received ASCT as consolidation, and those without bcl-2 overexpression (bcl-2-) conventional chemotherapy.	asct	36-40	BCL2 apoptosis regulator	Homo sapiens	11-16
11477443-4	2001	Our results suggest that patients with metastatic breast cancer and high soluble plasma HER-2 have a significantly poorer overall (OS) and progression-free survival (PFS) following high-dose chemotherapy with paclitaxel and ASCT.	asct	224-228	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-93